Related Experiment Video
Updated: Jun 11, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis
Lindsey A Chew1,2, Daniel Grigsby3, C Garren Hester1
1Department of Ophthalmology, Duke Eye Center, Duke University Medical Center, Durham, NC 27710.
Insights
Adeno-associated virus delivery of truncated complement factor H (tCFH) effectively reversed C3 glomerulonephritis in mice. This gene therapy approach shows promise for treating C3G and age-related macular degeneration.
Area of Science:
- Ophthalmology
- Nephrology
- Gene Therapy
Background:
- Age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) share complement dysregulation pathways.
- Current therapies for C3G are limited, and previous attempts using exogenous complement factor H (CFH) faced immune rejection.
- C3G is characterized by complement alternative pathway dysregulation.
Purpose of the Study:
- To investigate adeno-associated virus (AAV)-mediated delivery of truncated CFH (tCFH) for treating C3G.
- To assess the efficacy and long-term safety of AAV-tCFH gene therapy in a mouse model.
- To explore AAV-tCFH as a potential therapy for both C3G and AMD.
Main Methods:
- Utilized a Cfh-/- mouse model of C3G.
- Administered various adeno-associated virus (AAV) vectors encoding truncated complement factor H (tCFH).
- Monitored complement pathway inhibition, disease reversal, and immune response.
Main Results:
- Long-term AAV-mediated delivery of tCFH successfully inhibited the complement alternative pathway.
- Reversal of C3G was achieved without evidence of immune rejection.
- Different AAV vectors demonstrated varying levels of efficiency and efficacy.
Conclusions:
- AAV-mediated tCFH gene therapy offers a promising strategy for C3G treatment, overcoming limitations of previous approaches.
- This study provides proof of concept for AAV-tCFH gene augmentation therapy for AMD.
- The findings support the development of novel gene therapies targeting complement dysregulation in both C3G and AMD patients.
Abstract:
Patients with both age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) are challenged by the absence of effective therapies to reverse and eliminate their disease burden. Capitalizing on complement dysregulation as both a significant risk factor for AMD and the known pathophysiology of C3G, we investigated the potential for adeno-associated virus (AAV) delivery of complement factor H (CFH) to rescue C3G in a Cfh-/- mouse model of C3G. While past efforts to treat C3G using exogenous human CFH resulted in limited success before immune rejection led to a foreign protein response, our findings demonstrate the capacity for long-term AAV-mediated delivery of truncated CFH (tCFH) to restore inhibition of the alternative pathway of complement and ultimately reverse C3G without immune rejection. Comparing results from the administration of several tCFH vectors also revealed significant differences in their relative efficiency and efficacy. These discoveries pave the way for subsequent development of AAV-mediated tCFH replacement therapy for patients with C3G, while simultaneously demonstrating proof of concept for a parallel AAV-mediated tCFH gene augmentation therapy for patients with AMD.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
